<DOC>
	<DOCNO>NCT01313520</DOCNO>
	<brief_summary>This study compare effect infliximab versus placebo synovial inflammation measure dynamic contrast enhance ( DCE ) -MRI one wrist . The primary hypothesis 14 week therapy , change baseline volume transfer rate enhance synovium large due treatment infliximab placebo .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Infliximab Changes Hand Wrist Magnetic Resonance Imaging ( MRI ) Participants With Active Rheumatoid Arthritis ( RA ) ( P08136 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Must clinical diagnosis rheumatoid arthritis least 6 month Must least 6 tender joint AND 6 swollen joint Has Creactive protein ≥ 1.0 mg/L OR Erythrocyte Sedimentation Rate ( ESR ) ≥ 28 mm/hr Baseline MRI must show evidence synovitis wrist Must screen laboratory test within acceptable level Women childbearing potential men must agree use medically accept method contraception prior enter study continue throughout study 6 week study completion Must meet tuberculosis ( TB ) screen criterion Have receive methotrexate therapy ≥ 3 month ; dose must stable least 8 week If take disease modify antirheumatic drug ( DMARD ) combination methotrexate must stable dose Must clinically acceptable 12 lead electrocardiogram ( ECG ) If take oral corticosteroid must stable dose equivalent ≤10 mg prednisone ( prednisolone ) per day ≥2 week If take daily nonsteroidal antiinflammatory drug ( NSAID ) must stable dose ≥2 week ; take NSAID asneeded basis must agree discontinue use least 3 day use acetaminophen breakthrough pain 3 day MRI clinic visit If receive biological therapy , last dose drug receive ≥ 3 month prior baseline visit AND reason discontinuation safety consideration OR lack efficacy Are pregnant , intend become pregnant , breastfeeding Has inflammatory arthritis RA Has uncontrolled hypertension Has moderate severe congestive heart failure Has history current sign and/or symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological , cerebral , psychiatric disease Has history demyelinate disease symptom suggestive multiple sclerosis optic neuritis Is currently participate another clinical study participate clinical study ( e.g. , laboratory clinical evaluation ) within 4 week Has history tumor exception adequately treat basal cell carcinoma carcinoma situ cervix Has history latent active granulomatous infection include histoplasmosis , coccidiomycosis Had nontuberculous mycobacterial infection opportunistic infection ( e.g . cytomegalovirus , Pneumocystis carinii , aspergillosis ) within 6 month Has history infect joint prosthesis remove replace Has know hypersensitivity human immunoglobulin proteins component infliximab Has receive rituximab natalizumab Has know claustrophobia contraindication MRI Does meet washout period guideline previous treatments/injections/vaccinations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>